A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM).

JOURNAL ARTICLE published 20 May 2017 in Journal of Clinical Oncology

Authors: Chris Twelves | Susan Short | Stephen Wright | Cannabinoid in Recurrent Glioma Study Group